New chemo combo aims to boost leukemia survival after transplant
NCT ID NCT07232953
First seen Nov 18, 2025 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This phase 2 trial tests a combination of two chemotherapy drugs, fludarabine and treosulfan, given before a stem cell transplant in adults aged 40-65 with acute myeloid leukemia (AML) in remission. The goal is to see if this conditioning regimen improves the chance of being alive and leukemia-free one year after transplant. About 82 participants will receive the treatment and be monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASST degli Spedali Civili di Brescia
Brescia, Lombardy, 25123, Italy
-
Azienda Ospedaliera S. Croce e Carle
Cuneo, Piedmont, 12100, Italy
-
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Veneto, 37126, Italy
-
Azienda Ospedaliera Universitaria di Modena
Modena, Emilia-Romagna, 41124, Italy
-
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Naples, Campania, 80131, Italy
-
Azienda Ospedaliero Universitaria Careggi
Florence, Tuscany, 50134, Italy
-
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Friuli Venezia Giulia, 33100, Italy
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
Milan, Lombardy, 20122, Italy
-
Grande Ospedale Metropolitano "Bianco Melacrino Morelli"
Reggio Calabria, Calabria, 89124, Italy
-
IRCCS Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
-
Ospedale C e G Mazzoni
Ascoli Piceno, The Marches, 63100, Italy
-
Ospedale dell'Angelo
Mestre, Veneto, 30174, Italy
-
Ospedali Riuniti di Ancona
Ancona, The Marches, 60126, Italy
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fludarabine and Treosulfan (chemotherapy drugs)
What this could lead to
If successful, this conditioning regimen could improve leukemia-free survival after stem cell transplant for AML patients.
What could go wrong
This is a phase 2 trial with only 82 participants, so results may not apply broadly. Chemotherapy can cause serious side effects like infection and organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.